PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 1, 1974Journal of Clinical Investigation539 citationsOpen Access

Measurement of Fibrinopeptide A in Human Blood

HNH. L. NosselIYI. YudelmanRCR E Canfield

Key Points

  • To adapt a radioimmunoassay for plasma fibrinopeptide A to clinical blood samples to directly quantify in vivo thrombin activity.
  • Extracted fibrinopeptide A (FPA) from clinical plasma samples by ethanol precipitation of cross-reacting fibrinogen followed by dialysis, yielding a 75% recovery rate.
  • Measured plasma FPA by radioimmunoassay in 30 healthy men, 12 patients with reduced fibrinogen or platelet counts, and 13 patients with normal or elevated fibrinogen (including 6 with venous thrombosis or pulmonary embolism).
  • Evaluated FPA clearance kinetics following infusion in 4 healthy controls and during heparin therapy in 6 patients with thromboembolism.
  • Plasma FPA levels were below 2 ng/ml in all 30 normal men (mean 0.5 ng/ml), while levels ranged from 4 to 289 ng/ml in 12 patients with reduced fibrinogen/platelets and 5 to 23 ng/ml in 13 patients with normal or elevated fibrinogen.
  • Plasma FPA showed an elimination half-life of 3 to 5 minutes in 4 healthy individuals, and heparin administration in 6 thromboembolism patients triggered a rapid decline matching this 3-to-5-minute rate.
  • FPA levels did not correlate with fibrinogen degradation products, demonstrating increased thrombin activity in several patients despite normal degradation product levels.

Abstract

Since thrombin cleaves fibrinopeptides A (FPA) and B from the NH(2)-terminal end of the fibrinogen molecule, measurement of fibrinopeptide levels in plasma may provide a direct index of thrombin action. Recently a radioimmunoassay for FPA has been developed, and in the present paper, we describe the application of this assay to the measurement of FPA levels in clinical blood samples. Since fibrinogen cross-reacts with antibodies to FPA, dialysis was used to extract the peptide from plasma. In vitro generation of FPA was prevented by removing the fibrinogen from the plasma by precipitation with ethanol before dialysis. The processing technique permitted recovery of 75% of FPA added to blood in vitro. Evidence that the immunoreactivity measured in plasma is due to FPA was provided by the results of experiments in which two antisera to FPA with different specificities showed comparable results and addition of thrombin caused no change in immunoreactivity. In contrast, extracts of streptokinasetreated plasma showed a five-fold increase in activity when treated with thrombin and markedly different immunoreactivity with the two antisera. Plasma FPA levels in 30 normal men were below 2 ng/ml, with a mean of 0.5 ng/ml. FPA levels in 12 patients with reduced fibrinogen levels or reduced platelet counts or both ranged between 4 and 289 ng/ml. FPA levels in 13 patients with normal or elevated fibrinogen levels, including 6 patients with clinical evidence of venous thrombosis or pulmonary embolism or both, ranged between 5 and 23 ng/ml. FPA and fibrinogen degradation product levels did not correlate, and in several patients, elevated FPA levels were found in the presence of normal fibrinogen degradation product levels. After infusion of FPA-containing solutions in four normal individuals, FPA showed a disappearance rate from the plasma consistent with a t((1/2)) of 3-5 min. Heparin infusions in six patients with venous thrombosis or pulmonary embolism or both and elevated FPA levels were followed by a prompt decline in FPA level at a mean rate equivalent to a 3-5 min t((1/2)).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nossel et al. (1974) studied this question.

synapsesocial.com/papers/6a01b8cef58f6e6cfdd8bb65https://doi.org/10.1172/jci107749
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Factors affecting fibrinopeptide-A levels in patients with venous thromboembolism during anticoagulant therapy1982 · 36 citations
  2. 2Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension.1990 · 133 citations
  3. 3Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.1989 · 105 citations
  4. 4Fibrinopeptide A: a marker of acute coronary thrombosis.1985 · 166 citations
  5. 5Plasma level changes of fibrinopeptide a after uncomplicated coronary angioplasty1993 · 12 citations